Latest Regulatory Engagement News

Critical Resources has defined a focused 2026 exploration program at its Mavis Lake lithium project while confirming an orogenic gold system in New Zealand and delivering promising early results from its solid-state lithium-ion battery evaluation.

Santana Minerals has finalised the second tranche of its A$130 million capital raising, issuing nearly 19 million shares and securing A$17.04 million before costs. The company confirms ongoing progress towards project construction scheduled for late 2026, supported by strong margins and green hydro power.

AdAlta’s subsidiary AdCella has completed its first Joint Development Committee meeting with Shanghai Cell Therapy Group, advancing the development of the CAR-T therapy BZDS1901 with potential timeline acceleration and reduced regulatory risks.

Native Mineral Resources has successfully poured 560 ounces of gold doré at its Blackjack plant and is on track to begin mining at Podosky in April, advancing multiple projects in Queensland.

Brazilian Rare Earths Limited has secured a key Trial Mining Licence for its Monte Alto project, marking a significant step toward commercial rare earths production in Brazil.

BlinkLab has enrolled its first participant in the pivotal FDA 510(k) validation study for its autism diagnostic aid, BlinkLab Dx1, aiming for regulatory submission by the end of 2026.

Latitude Group Holdings Limited has launched an offer to raise approximately $100 million through Capital Notes 2, a new series of perpetual, subordinated, unsecured convertible notes. Existing Capital Notes 1 holders are invited to reinvest in the new notes, which feature discretionary quarterly distributions and potential conversion to ordinary shares.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

Lakes Blue Energy has temporarily halted gas flow testing at its Wombat-5 well to conduct extended pressure analysis, planning a perforation program to enhance production prospects.

Pancontinental Energy has won a crucial 12-month extension for its PEL 87 offshore Namibia exploration licence, enabling further seismic analysis and drilling preparations. This extension keeps the project on track as the company seeks a farmin partner to advance exploration.

Dimerix Limited is set to conduct a blinded statistical review of its pivotal Phase 3 ACTION3 study in March 2026, aiming to confirm the trial remains powered to demonstrate the primary endpoint of proteinuria reduction in FSGS patients.

Patrys has initiated manufacturing and regulatory steps for RLS-2201, its injectable Quetiapine formulation targeting delirium, aiming for Phase 0 trials in the second half of 2026.